J. Litton Mark's most recent trade in Athira Pharma Inc was a trade of 10,834 Common Stock done . Disclosure was reported to the exchange on Dec. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 10,834 | 43,414 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 10,834 | 0 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.88 per share. | 31 Dec 2025 | 2,586 | 40,828 | - | 6.9 | 17,792 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Dec 2025 | 133,526 | 133,526 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 108,334 | 350,925 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 108,334 | 108,333 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.29 per share. | 30 Jun 2025 | 25,123 | 325,802 | - | 0.3 | 7,374 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 333,815 | 333,815 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 222,543 | 222,543 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 108,333 | 267,698 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 108,333 | 216,667 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 25,107 | 242,591 | - | 0.6 | 14,108 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2024 | 325,000 | 325,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 20,000 | 164,397 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 5,032 | 159,365 | - | 0.6 | 2,848 | Common Stock |
| Athira Pharma Inc | Mark Litton J. | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Litton Mark J. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,000 | 149,217 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark J. Litton | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,000 | 149,217 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark Litton J. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 4,820 | 144,397 | - | 2.9 | 14,026 | Common Stock |
| Athira Pharma Inc | J. Litton Mark | Director, CEO | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 4,820 | 144,397 | - | 2.9 | 14,026 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 425,000 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 2.74 per share. | 27 Jan 2023 | 662 | 129,217 | - | 2.7 | 1,814 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 12.51 per share. | 27 Jan 2022 | 885 | 115,758 | - | 12.5 | 11,071 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 50,440 | 100,880 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 17 Aug 2021 | 50,440 | 114,873 | - | 1.4 | 68,094 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 14.45 per share. | 17 Aug 2021 | 867 | 64,433 | - | 14.4 | 12,528 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) |